Çocuklarda Santral Sinir Sistemi Demiyelinizan Hastalıklarında Tanımlamalar ve İzole Klinik Sendrom
Özet
Çocukluk çağı akkiz demiyelinizan sendromları (ADS), santral sinir sisteminin inflamatuar hastalıklarını kapsayan ve ADEM, MS, NMOSD gibi çeşitli klinik tablolarla kendini gösteren süreçlerdir. Tanısal süreçte MRG bulguları ve serolojik belirteçler kritik öneme sahip olup, metabolik veya genetik hastalıklardan ayırt edilmesi tedavi başarısı için temel teşkil eder. İzole klinik sendromlar MS ve diğer multifazik hastalıkların habercisi olabileceğinden, hastaların klinik ve radyolojik verilerle uzun dönem takibi zorunludur. Erken müdahale ve doğru tedavi algoritmaları, özellikle pediatrik grupta kalıcı nörolojik sekelleri minimize etmek için hayati niteliktedir.
Pediatric acquired demyelinating syndromes (ADS) encompass inflammatory conditions of the central nervous system that present with diverse clinical manifestations such as ADEM, MS, and NMOSD. Diagnosis relies heavily on MRI imaging and serological markers, requiring a careful distinction from metabolic or genetic disorders to ensure appropriate clinical management. Since clinically isolated syndromes can be the initial sign of MS or other multiphasic diseases, close long-term monitoring of clinical and radiological findings is essential. Early diagnosis and strategic therapeutic interventions are crucial for preventing long-term neurological disability in pediatric patients.
Referanslar
Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009;72:232-239.
Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF, et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. J Neurol 2012;259:1929-1935.
Langer-Gould A, Zhang JL, Chung J, Yeung Y, Waubant E, Yao J. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology 2011;77:1143-1148.
Absoud M, Lim MJ, Chong WK, et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler 2013;19:76-86.
de Mol CL, Wong YYM, van Pelt ED, et al. Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study. J Neurol 2018;265:1310-1319.
Yamaguchi Y, Torisu H, Kira R, et al. A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology 2016;87:2006-2015.
Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007;68:S7-12.
Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013;19:1261-1267.
Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013;9:455-461.
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-189.
O'Mahony J, Shroff M, Banwell B. Mimics and rare presentations of pediatric demyelination. Neuroimaging Clin N Am 2013;23:321-336.
Waters P, Fadda G, Woodhall M, et al. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurol 2020;77:82-93.
Hintzen RQ, Dale RC, Neuteboom RF, Mar S, Banwell B. Pediatric acquired CNS demyelinating syndromes: Features associated with multiple sclerosis. Neurology 2016;87:S67-73.
Mikaeloff Y, Suissa S, Vallée L, et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr 2004;144:246-252.
Neuteboom RF, Boon M, Catsman Berrevoets CE, et al. Prognostic factors after a first attack of inflammatory CNS demyelination in children. Neurology 2008;71:967-973.
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162-173.
Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 2017;140:3128-3138.
Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, et al. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 2016;22:174-184.
Sugimoto T, Ishibashi H, Hayashi M, et al. A case of anti-MOG antibody-positive unilaterally dominant meningoencephalitis followed by longitudinally extensive transverse myelitis. Mult Scler Relat Disord 2018;25:128-130.
Zhou J, Tan W, Tan SE, Hu J, Chen Z, Wang K. An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis. J Neuroimmunol 2018;320:107-110.
Waldman AT, Stull LB, Galetta SL, Balcer LJ, Liu GT. Pediatric optic neuritis and risk of multiple sclerosis: meta-analysis of observational studies. J aapos 2011;15:441-446.
Duignan SM, Hemingway CA. Paediatric acquired demyelinating syndromes. Paediatrics and Child Health 2019;29:468-475.
Chitnis T. Pediatric Central Nervous System Demyelinating Diseases. Continuum (Minneap Minn) 2019;25:793-814.
Dale RC, Pillai SC. Early relapse risk after a first CNS inflammatory demyelination episode: examining international consensus definitions. Dev Med Child Neurol 2007;49:887-893.
Alper G, Heyman R, Wang L. Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow-up: comparison of presenting features. Dev Med Child Neurol 2009;51:480-486.
Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology 2006;67:258-262.
Verhey LH, Branson HM, Shroff MM, et al. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol 2011;10:1065-1073.
Alper G, Petropoulou KA, Fitz CR, Kim Y. Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings. Mult Scler 2011;17:74-80.
Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol 2012;11:157-169.
Metz LM, Li DKB, Traboulsee AL, et al. Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. N Engl J Med 2017;376:2122-2133.
London F, Zéphir H, Drumez E, et al. Optical coherence tomography: a window to the optic nerve in clinically isolated syndrome. Brain 2019;142:903-915.
Miller AE, Vermersch P, Kappos L, et al. Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study(★★). Mult Scler Relat Disord 2019;33:131-138.
Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-1511.
Metz LM. Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis. Continuum (Minneap Minn) 2019;25:670-688.
